ME02474B - Terapijski režimi - Google Patents

Terapijski režimi

Info

Publication number
ME02474B
ME02474B MEP-2016-149A MEP14916A ME02474B ME 02474 B ME02474 B ME 02474B ME P14916 A MEP14916 A ME P14916A ME 02474 B ME02474 B ME 02474B
Authority
ME
Montenegro
Prior art keywords
dosage form
unit dosage
use according
compound
oral administration
Prior art date
Application number
MEP-2016-149A
Other languages
German (de)
English (en)
French (fr)
Inventor
Louis O'dea
C Richard Lyttle
Jonathan Guerriero
Original Assignee
Radius Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Health Inc filed Critical Radius Health Inc
Publication of ME02474B publication Critical patent/ME02474B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (10)

1.Jedinični dozni oblik koji obuhvata od 0,9 do 1,1 mg, od 2,2 do 2,8 mg, od 4,4 do 5,6 mg ili od 9 do 11mg jedinjenja formule I kao njegove dihidrohloridne soli za upotrebu u postupku tretiranja vazomotornih poremećaja u predmenopauznom ili postmenopauznom stanju žene kojoj je to potrebno, pri čemu postupak obuhvata davanje pacijentu jedanput dnevno pomenutog jediničnog doznog oblika.
2.Upotreba jedinjenja formule I kao njegove dihidrohloridne soli u proizvodnji leka za tretiranje vazomotornih poremećaja u predmenopauznom ili postmenopauznom stanju žene kojoj je to potrebno, pri čemu je lek jedinični dozni oblik koji obuhvata od 0,9 do 1,1 mg, od 2,2 do 2,8 mg, od 4,4 do 5,6 mg ili od 9 do 11 mg pomenutog jedinjenja, i gde postupak obuhvata davanje pacijentu jedanput dnevno pomenutog jediničnog doznog oblika.
3.Jedinični dozni oblik za upotrebu prema zahtevu 1, ili upotreba prema zahtevu 2, pri čemu jedinični dozni oblik obuhvata 1, 2,5 , 5 ili 10 mg jedinjenja formule I kao njegove dihidrohloridne soli.
4.Jedinični dozni oblik za upotrebu prema zahtevu 1, ili upotreba prema zahtevu 2, pri čemu jedinični dozni oblik obuhvata 10 mg jedinjenja formule I kao njegove dihidrohloridne soli.
5.Jedinični dozni oblik za upotrebu ili upotreba prema zahtevima 1 do 4, koji dalje obuhvata jedan ili više farmaceutski prihvatljivih ekscipijenata.
6.Jedinični dozni oblik prema zahtevu 5, pri čemu je jedinični dozni oblik tableta ili kapsula pogodna za oralnu primenu.
7.Jedinični dozni oblik prema zahtevu 6, pri čemu se nakon oralne primene jediničnog doznog oblika više od 50% rastvara u želucu pre nego što se oslobodi u tankim crevima.
8.Jedinični dozni oblik prema zahtevu 7, pri čemu jedinični dozni oblik nije obložen oblogom otpornom na kiseline.
9.Jedinični dozni oblik za upotrebu ili upotreba prema bilo kom od zahteva 1 do 4, pri čemu se jedinični dozni oblik primenjuje oralno, jedanput dnevno; i opciono pri čemu je jedinični dozni oblik tableta ili kapsula pogodna za oralnu primenu.
10.Jedinični dozni oblik za upotrebu ili upotreba prema zahtevu 9, pri čemu je jedinični dozni oblik tableta ili kapsula pogodna za oralnu primenu, a koja se više od 50% rastvara u želucu pre nego što se oslobodi u tankim crevima, a opciono pri čemu jedinični dozni oblik nije obložen oblogom otpornom na kiseline.
MEP-2016-149A 2010-05-12 2011-05-12 Terapijski režimi ME02474B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33409510P 2010-05-12 2010-05-12
PCT/US2011/036311 WO2011143469A1 (en) 2010-05-12 2011-05-12 Therapeutic regimens
EP11781299.0A EP2568806B1 (en) 2010-05-12 2011-05-12 Therapeutic regimens

Publications (1)

Publication Number Publication Date
ME02474B true ME02474B (me) 2017-02-20

Family

ID=44914714

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-149A ME02474B (me) 2010-05-12 2011-05-12 Terapijski režimi

Country Status (17)

Country Link
US (2) US20130053448A1 (me)
EP (2) EP2568806B1 (me)
CA (1) CA2799183A1 (me)
CY (1) CY1117893T1 (me)
DK (1) DK2568806T3 (me)
ES (1) ES2585884T3 (me)
HR (1) HRP20160929T1 (me)
HU (1) HUE030072T2 (me)
LT (1) LT2568806T (me)
ME (1) ME02474B (me)
MX (1) MX342898B (me)
PL (1) PL2568806T3 (me)
PT (1) PT2568806T (me)
RS (1) RS54993B1 (me)
SI (1) SI2568806T1 (me)
SM (1) SMT201600263B (me)
WO (1) WO2011143469A1 (me)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933130B2 (en) 2006-06-23 2015-01-13 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
SI2568806T1 (sl) 2010-05-12 2016-09-30 Radius Health, Inc. Režimi zdravljenja
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
PT3122426T (pt) 2014-03-28 2023-02-28 Univ Duke Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénio
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
HRP20220619T1 (hr) 2016-06-22 2023-02-03 Ellipses Pharma Ltd Postupci za liječenje ar+ raka dojke
ES2981967T3 (es) 2017-01-05 2024-10-14 Radius Pharmaceuticals Inc Formas polimórficas de RAD1901-2HCl
JP7473486B2 (ja) 2018-07-04 2024-04-23 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形形態
JOP20210218A1 (ar) 2019-02-12 2023-01-30 Radius Pharmaceuticals Inc عمليات ومركبات
WO2024252263A1 (en) * 2023-06-05 2024-12-12 Berlin-Chemie Ag Solid elacestrant dihydrochloride compositions, methods of making the same, and methods of treatment using the same

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1547758A (en) 1975-07-29 1979-06-27 Shell Int Research Herbicidal composition
JPH01261381A (ja) 1988-04-12 1989-10-18 Nippon Soda Co Ltd オキサ（チア）ジアゾール誘導体、その製造方法及び殺ダニ剤
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
GB9310635D0 (en) 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds
DE19517430A1 (de) 1995-05-12 1996-11-14 Boehringer Mannheim Gmbh Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode
UA51652C2 (uk) 1995-06-08 2002-12-16 Новартіс Аг Спосіб гідрування імінів
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5969095A (en) 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
BR9710988A (pt) 1996-06-27 2002-01-15 Ligand Pharm Inc Método e compostos moduladores receptores de androgênio
US20090264534A1 (en) 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
FR2770842B1 (fr) 1997-11-13 1999-12-17 Oreal Nouveaux composes derives de n-aryl 2-hydroxy alkylamides
EP0922467A3 (en) 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
JP4154017B2 (ja) 1997-12-30 2008-09-24 久光製薬株式会社 イオントフォレーシス装置および薬物ユニット
US6159959A (en) 1999-05-06 2000-12-12 American Home Products Corporation Combined estrogen and antiestrogen therapy
WO2001036039A2 (en) 1999-11-17 2001-05-25 Novartis Ag Iontophoretic transdermal delivery of peptides
US6544553B1 (en) * 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
ATE289300T1 (de) 1999-12-30 2005-03-15 Signal Pharm Inc Verbindungen und verfahren zur modulation von estrogen rezeptoren
AU2991301A (en) 2000-01-28 2001-08-07 Endorecherche Inc. Selective estrogen receptor modulators in combination with estrogens
AU8821301A (en) 2000-06-28 2002-01-08 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, design and use
ATE485837T1 (de) 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
AU2001285230C1 (en) 2000-08-24 2008-03-13 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
BR0114909A (pt) 2000-10-26 2004-02-03 Alza Corp Dispositivos de distribuição de drogas transdérmicas possuindo microprotuberâncias revestidas
US6670386B2 (en) 2001-07-31 2003-12-30 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
EP1418900A4 (en) 2001-08-13 2006-01-25 Merck & Co Inc SELECTIVE ESTROGEN RECEPTOR MODULATORS
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
WO2003063859A1 (en) 2002-01-14 2003-08-07 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
US6933321B2 (en) 2002-02-15 2005-08-23 Endorecherche, Inc. Antiandrogenic biphenyls
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
SI1501819T1 (sl) 2002-04-24 2011-01-31 Merck Sharp & Dohme Modulatorji estrogen receptorjev
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
TW200307553A (en) 2002-05-24 2003-12-16 Akzo Nobel Nv Treatment of post-menopausal complaints in breast cancer patients
WO2003105772A2 (en) 2002-06-13 2003-12-24 Beth Israel Deaconess Medical Center, Inc. Analogs of parathyroid hormone and pth-related protein as bone anabolic agents
DK1557411T3 (da) 2002-07-12 2012-11-05 Astellas Pharma Inc N-phenyl-(2r,5s)-dimethylpiperazin-derivat
WO2004016576A1 (ja) 2002-08-12 2004-02-26 Takeda Pharmaceutical Company Limited 縮合ベンゼン誘導体および用途
US7383084B2 (en) 2002-10-31 2008-06-03 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
IL152574A (en) 2002-10-31 2009-09-22 Transpharma Medical Ltd A system for passing through the skin of dry items or dried medicines
US8133505B2 (en) 2002-10-31 2012-03-13 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
US7662404B2 (en) 2002-10-31 2010-02-16 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
JP2006513159A (ja) 2002-11-01 2006-04-20 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体モジュレーターとしてのカルボニルアミノ−ベンズイミダゾール誘導体
UA79504C2 (en) 2002-11-07 2007-06-25 Organon Nv Indols for treating diseases associated with androgen receptors
AU2003302084A1 (en) 2002-11-15 2004-06-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
WO2004058682A1 (ja) 2002-12-26 2004-07-15 Eisai Co., Ltd. 選択的エストロゲン受容体モジュレーター
US7741352B2 (en) 2003-03-11 2010-06-22 Neurosearch A/S KCNQ channel modulating compounds and their pharmaceutical use
US20060142387A1 (en) 2003-06-10 2006-06-29 Rodolfo Cadilla Chemical compounds
WO2005000795A2 (en) 2003-06-10 2005-01-06 Smithkline Beecham Corporation Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators
FI20030958A0 (fi) 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
MXPA06000281A (es) 2003-06-30 2006-07-03 Johnson & Johnson Formulaciones para microproyecciones revestidas que contienen contraiones no volatiles.
JP2007525472A (ja) * 2003-07-04 2007-09-06 ニコメド ダンマーク エイピーエス 経口使用のための副甲状腺ホルモン（ｐｔｈ）含有医薬組成物
AU2004272007B2 (en) 2003-09-10 2009-05-28 Merck Sharp & Dohme Corp. 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
WO2005044333A2 (en) 2003-10-31 2005-05-19 Alza Corporation Self-actuating applicator for microprojection array
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
CN100548228C (zh) 2003-11-13 2009-10-14 阿尔扎公司 用于透皮递送的组合物和装置
BRPI0416208A (pt) 2003-11-20 2006-12-26 Warner Lambert Co moduladores de receptores de androgênio
IL159273A0 (en) 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
WO2005060956A1 (en) 2003-12-12 2005-07-07 University Of Maryland, Baltimore IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN
KR101536701B1 (ko) 2004-01-07 2015-07-14 앙도르쉐르슈 인코포레이티드 헬릭스 12 배향형 스테로이드계 약학 제품
UA85862C2 (uk) 2004-01-22 2009-03-10 Елі Ліллі Енд Компані Селективні модулятори рецепторів естрогену для лікування вазомоторних симптомів
IL160033A0 (en) 2004-01-25 2004-06-20 Transpharma Medical Ltd Transdermal delivery system for polynucleotides
US20050182105A1 (en) 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
JP4805909B2 (ja) 2004-03-03 2011-11-02 スミスクライン ビーチャム コーポレーション 選択的アンドロゲン受容体モジュレーターとしてのアニリン誘導体
US7388027B2 (en) 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
GB0405033D0 (en) 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
JP2007223901A (ja) 2004-03-24 2007-09-06 Takeda Chem Ind Ltd 複素環化合物およびその用途
CA2562132A1 (en) 2004-04-08 2005-10-27 Merck & Co., Inc. 17 beta-acetamide-4-azasteroids as androgen receptor modulators
TW200602317A (en) 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
WO2005111028A1 (en) 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
CA2565544A1 (en) 2004-05-11 2005-11-17 Pfizer Products Inc. Benzonitrile derivatives to treat musculoskeletal frailty
EP1744683B1 (en) 2004-05-13 2016-03-16 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
WO2005115361A2 (en) 2004-05-17 2005-12-08 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
WO2005116001A1 (en) 2004-05-29 2005-12-08 7Tm Pharma A/S Substituted thiazoleacetic as crth2 ligands
CA2543827C (en) 2004-06-07 2010-03-09 James T. Dalton Selective androgen receptor modulators and methods of use thereof
EP1791821B1 (en) 2004-09-10 2013-06-05 Janssen Pharmaceutica NV Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (sarms)
CN101072780B (zh) 2004-09-20 2010-06-23 詹森药业有限公司 用作类固醇性激素受体调节剂的新的含杂原子的四环衍生物
CN101065363B (zh) 2004-09-30 2012-05-02 詹森药业有限公司 可用作选择性雄激素受体调节剂（sarms）的新苯并咪唑衍生物
US8143425B2 (en) 2004-10-12 2012-03-27 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
WO2006044707A1 (en) 2004-10-13 2006-04-27 Smithkline Beecham Corporation Chemical compounds
JP2008518968A (ja) 2004-10-29 2008-06-05 メルク エンド カムパニー インコーポレーテッド アンドロゲン受容体モジュレーターとしてのｎ−（ピリジン−３−イル）−２−フェニルブタンアミド
WO2006055184A2 (en) 2004-11-16 2006-05-26 Janssen Pharmaceutica N.V. Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms)
EP1848498A4 (en) 2004-11-18 2009-12-16 Transpharma Medical Ltd ASSOCIATED MICRO-CHANNEL PRODUCTION AND IONTOPHORESIS FOR TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS
CA2588607A1 (en) 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
RU2007130558A (ru) 2005-01-10 2009-02-20 Акэдиа Фармасьютикалз Инк. (Us) Производные аминофенола в качестве селективных модуляторов андрогеновых рецепторов
JP2008536868A (ja) 2005-04-15 2008-09-11 スミスクライン・ビーチャム・コーポレイション シアノアリールアミン
DK1891038T3 (da) 2005-05-13 2009-01-19 Lilly Co Eli Substituerede n-arylpyrrolidiner som selektive androgenreceptormodulatorer
EP1888512A2 (en) 2005-06-06 2008-02-20 Smithkline Beecham Corporation Chemical compounds
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
BRPI0611705A2 (pt) 2005-06-24 2016-11-16 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto
AR057656A1 (es) 2005-07-01 2007-12-12 Ligand Pharm Inc Compuestos moduladores de receptores de androgeno y metodods relacionados
US8592452B2 (en) 2005-08-01 2013-11-26 Takeda Pharmaceutical Company Limited Cyclic amine compound
JP2008303145A (ja) 2005-09-22 2008-12-18 Takeda Chem Ind Ltd Ｇｒｋ阻害剤からなる強心薬
US7776859B2 (en) 2005-10-14 2010-08-17 Bristol-Myers Squibb Company Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function
EP1948139A4 (en) 2005-11-18 2012-04-04 3M Innovative Properties Co COATING COMPOSITIONS, COATINGS DERIVED THEREFROM, AND MICRO-NETWORKS COMPRISING SUCH COATINGS
TW200730505A (en) 2005-12-07 2007-08-16 Merck & Co Inc Polymorphs of an androgen receptor modulator
US8632801B2 (en) 2005-12-28 2014-01-21 Alza Corporation Stable therapeutic formulations
NZ570539A (en) 2006-01-24 2011-07-29 Janssen Pharmaceutica Nv 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS)
AU2007220419B2 (en) 2006-03-03 2012-03-15 Orion Corporation Selective androgen receptor modulators
JP2009530307A (ja) 2006-03-15 2009-08-27 アルザ コーポレイション 骨減少症を予防し、または治療するための副甲状腺ホルモン薬の経皮送達のための装置、並びに方法
WO2007124411A1 (en) 2006-04-20 2007-11-01 3M Innovative Properties Company Device for applying a microneedle array
US8933130B2 (en) * 2006-06-23 2015-01-13 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
CA2658394C (en) 2006-07-12 2016-08-16 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
MX2009000715A (es) 2006-07-19 2009-07-22 Osurf Ohio State University Re Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos.
PT2054049E (pt) 2006-08-24 2016-06-02 Univ Tennessee Res Found Acilanilidas substituídas e métodos de utilização das mesmas
JP5275236B2 (ja) 2006-09-29 2013-08-28 スミスクライン ビーチャム コーポレーション 置換されたインドール化合物
JP5375611B2 (ja) 2006-10-03 2013-12-25 ラジウス ヘルス，インコーポレイテッド 骨同化作用を有するタンパク質のための薬物送達方法
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
WO2008044033A1 (en) 2006-10-11 2008-04-17 Astrazeneca Ab Amide derivatives
UA98777C2 (en) 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
WO2008121602A1 (en) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
WO2008124000A2 (en) 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
WO2008128100A1 (en) 2007-04-13 2008-10-23 The Regents Of The University Of California Small-molecule inhibitors of the androgen receptor
US9114238B2 (en) 2007-04-16 2015-08-25 Corium International, Inc. Solvent-cast microprotrusion arrays containing active ingredient
KR20100049644A (ko) 2007-08-07 2010-05-12 다케다 야쿠힌 고교 가부시키가이샤 안드로겐 수용체 조절제로서의 피롤리딘-2-온 유도체
US20090117158A1 (en) 2007-10-23 2009-05-07 Mahmoud Ameri Transdermal sustained release drug delivery
WO2009065600A2 (en) 2007-11-21 2009-05-28 Technische Universität Dresden Means for treating myosin-related diseases
US8003649B2 (en) 2007-12-21 2011-08-23 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155
US8067448B2 (en) 2008-02-22 2011-11-29 Radius Health, Inc. Selective androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2009133861A1 (ja) 2008-04-28 2009-11-05 武田薬品工業株式会社 環状アミン化合物
US20110124617A1 (en) 2008-05-09 2011-05-26 Lyttle C Richard Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent
WO2009140448A1 (en) 2008-05-16 2009-11-19 Eli Lilly And Company Tetrahydrocyclopenta[b]indole androgen receptor modulators
WO2010022176A1 (en) 2008-08-19 2010-02-25 Ferring International Center S.A. Methods of treatment for skeletal conditons
US8329649B2 (en) 2008-11-04 2012-12-11 Aska Pharmaceutical Co., Ltd. Aqueous composition containing follicle-stimulating hormone and histidine
JP5902390B2 (ja) 2008-12-26 2016-04-13 久光製薬株式会社 マイクロニードルデバイス
US20100226966A1 (en) 2009-03-03 2010-09-09 Daddona Peter E Method for transdermal controlled release drug delivery
WO2010118287A1 (en) 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
US20110172609A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
MX338831B (es) 2010-02-04 2016-05-03 Radius Health Inc Moduladores selectivos de receptores de androgenos.
IE20100174A1 (en) 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides
US9687641B2 (en) 2010-05-04 2017-06-27 Corium International, Inc. Method and device for transdermal delivery of parathyroid hormone using a microprojection array
SI2568806T1 (sl) 2010-05-12 2016-09-30 Radius Health, Inc. Režimi zdravljenja
AU2011258288B2 (en) 2010-05-28 2015-02-12 Kindeva Drug Delivery L.P. Aqueous formulations for coating microneedle arrays
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
WO2012075375A1 (en) 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
US20130006217A1 (en) 2011-04-22 2013-01-03 Gary Hattersley METHOD OF DRUG DELIVERY FOR PTH, PTHrP AND RELATED PEPTIDES
AU2012345768B2 (en) 2011-11-30 2016-05-12 Kindeva Drug Delivery L.P. Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same

Also Published As

Publication number Publication date
CA2799183A1 (en) 2011-11-17
EP2568806B1 (en) 2016-05-11
SMT201600263B (it) 2016-08-31
MX2012013014A (es) 2013-02-27
HUE030072T2 (en) 2017-04-28
EP3106159A1 (en) 2016-12-21
EP2568806A1 (en) 2013-03-20
EP2568806A4 (en) 2013-09-11
PL2568806T3 (pl) 2017-03-31
RS54993B1 (sr) 2016-11-30
US9555014B2 (en) 2017-01-31
LT2568806T (lt) 2016-09-26
CY1117893T1 (el) 2017-05-17
PT2568806T (pt) 2016-08-05
US20160022608A1 (en) 2016-01-28
HRP20160929T1 (hr) 2016-10-07
ES2585884T3 (es) 2016-10-10
WO2011143469A1 (en) 2011-11-17
US20130053448A1 (en) 2013-02-28
DK2568806T3 (en) 2016-08-15
SI2568806T1 (sl) 2016-09-30
MX342898B (es) 2016-10-18
WO2011143469A8 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
ME02474B (me) Terapijski režimi
FI3936130T3 (fi) Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
JP2015038135A5 (me)
ME02179B (me) Metoda za lečenje atrijalne fibrilacije
PH12015502134A1 (en) Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
JP2011068653A5 (me)
AU2012284627A8 (en) Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans
NZ714963A (en) Compositions and methods for treating anemia
JP2013231087A5 (me)
HRP20201316T1 (hr) Novi modulatori receptora sfingozin-fosfata
JP2015522630A5 (me)
TN2011000307A1 (en) Galenic formulation of organic compounds
JP2013209384A5 (me)
FI3710000T3 (fi) Tradipitantti käytettäväksi gastropareesin hoidossa
RU2014141893A (ru) Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких
JP2019218379A5 (me)
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
HRP20171742T4 (hr) 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom
HRP20211046T1 (hr) Upotreba derivata benzimidazola kod noćnog proboja kiseline
JP2016505050A5 (me)
JP2016507500A5 (me)
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
RU2020123405A (ru) Лекарственная композиция для профилактики или лечения вторичного гиперпаратиреоза при поддерживающем диализе
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
HRP20161796T1 (hr) Farmaceutski pripravak za primjenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želučane premosnice